

Supplementary data:*Changes of pregnancy management and outcomes in PAH-CHD women before and after 2006*

We observed no significant differences in maternal and foetal outcomes and pregnancy management between period before 2006 and period after 2006. However, more patients were treated with phosphodiesterase type 5-inhibitor after 2006, and cardiac complications were less severe during this recent period (Table 5).

	Era before 2006	Era after 2006
	n=14	n=14
Maternal outcomes		
Death, n	1	0
Cardiovascular complications, n	3	3
HF or cardiogenic shock, n	3	1
Foetal outcomes		
	n=8	n=10
Death	0	0
Gestational age, mean±SD, WG	34±4	33±4
Prematurity, n	6	8
SGA	4	3
Pregnancy management		
Mode of delivery (caesarean /vaginal)	5/2	7/3

Anesthesia (general/epidural/spinal/no)	1/2/3/0*	2/4/3/1
Advanced PAH therapy	0	3
Anticoagulation or antiplatelet therapy	2	4
Preventive antibiotic	3	4

Table 5: Comparison of maternal and fetal outcomes and pregnancy management before and after 2006. *Data about anesthesia were missing for one patient. PAH: pulmonary arterial hypertension, SGA: small for gestational age, WG: week of gestation.